CIK 0001818794 · Large accelerated filer
Dyne Therapeutics, Inc.
Sign in to watch- Ticker
- DYN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364883909
- Phone
- (781) 786-8230
- Business address
- 1560 TRAPELO ROAD, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $40,000
- in 1 filing
- Open-market sales, last 90 days
- $247,777
- in 3 filings, $248K under 10b5-1 plans
Net −$207,777. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-07 | Farwell Wildon Chief Medical Officer | Sale 10b5-1 | −1,557 | $26.20 | $41K | 153,175 |
| 2024-03-07 | McNeill Jonathan Chief Business Officer | Sale 10b5-1 | −2,434 | $25.85 | $63K | 141,184 |
| 2024-03-07 | Scalzo Richard William SVP, Head of Finance & Admin. | Sale 10b5-1 | −2,273 | $25.85 | $59K | 121,955 |
| 2024-03-01 | Rhodes Jason P Director | Sale 10b5-1 | −29,435 | $30.05 | $885K | 1,458,691 |
| 2024-03-01 | Rhodes Jason P Director | Sale 10b5-1 | −17,099 | $30.05 | $514K | 847,388 |
| 2024-03-01 | Atlas Venture Opportunity Fund I, L.P. 10% owner | Sale 10b5-1 | −29,435 | $30.05 | $885K | 1,458,691 |
| 2024-03-01 | Atlas Venture Opportunity Fund I, L.P. 10% owner | Sale 10b5-1 | −17,099 | $30.05 | $514K | 847,388 |
| 2024-03-01 | Brumm Joshua T CEO & President | Option exercise 10b5-1 | +94,480 | $5.54 | $523K | 657,951 |
| 2024-03-01 | Brumm Joshua T CEO & President | Sale 10b5-1 | −18,976 | $28.25 | $536K | 638,975 |
| 2024-03-01 | Brumm Joshua T CEO & President | Sale 10b5-1 | −74,090 | $29.23 | $2.2M | 564,885 |
| 2024-03-01 | Brumm Joshua T CEO & President | Sale 10b5-1 | −1,414 | $29.70 | $42K | 563,471 |
| 2024-03-01 | Brumm Joshua T CEO & President | Option exercise · Stock option (right to buy) 10b5-1 | −57,843 | 44,500 | ||
| 2024-03-01 | Brumm Joshua T CEO & President | Option exercise · Stock option (right to buy) 10b5-1 | −36,637 | 342,681 | ||
| 2024-03-01 | McNeill Jonathan Chief Business Officer | Option exercise 10b5-1 | +24,260 | $0.73 | $18K | 167,878 |
| 2024-03-01 | McNeill Jonathan Chief Business Officer | Sale 10b5-1 | −14,103 | $28.25 | $398K | 153,775 |
| 2024-03-01 | McNeill Jonathan Chief Business Officer | Sale 10b5-1 | −8,715 | $29.06 | $253K | 145,060 |
| 2024-03-01 | McNeill Jonathan Chief Business Officer | Sale 10b5-1 | −1,442 | $29.70 | $43K | 143,618 |
| 2024-03-01 | McNeill Jonathan Chief Business Officer | Option exercise · Stock option (right to buy) 10b5-1 | −24,260 | 0 | ||
| 2024-03-01 | Scalzo Richard William SVP, Head of Finance & Admin. | Option exercise 10b5-1 | +9,311 | $1.03 | $10K | 133,539 |
| 2024-03-01 | Scalzo Richard William SVP, Head of Finance & Admin. | Sale 10b5-1 | −8,747 | $28.22 | $247K | 124,792 |
Page 22 of 29 · 561 trades